BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced additional data supporting the long-term efficacy of TEPEZZA for the treatment of TED.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc., announced the appointment of highly accomplished molecular biologist Suman M. Verma, M.D., Ph.D. as Lucid’s Chief Scientific Officer and PAVmed’s VP, Molecular Diagnostics.

Throughout the pandemic, the Government of Canada has worked closely with vaccine manufacturers to negotiate the delivery of vaccines to Canada as quickly as possible.

Ernest Pharmaceuticals and the Forbes Lab at UMass/Amherst developed a salmonella-based cancer therapy that selectively invades cancer cells, then produces and delivers a cancer drug to kill the tumor.

CVRx, Inc., a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced that it plans to release third quarter financial and operating results after market close on Thursday, November 4, 2021.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced the appointment of Mark Litton, Ph.D., M.B.A. as Chief Executive Officer of Athira.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to the discovery and optimization of CK-3828136 (CK-136) will be presented at the 2021 Medicinal Chemistry Gordon Research Conference.

Metacrine, Inc. (NASDAQ:MTCR), today reported interim results from a Phase 2a clinical trial evaluating the efficacy and safety of MET642, a farnesoid X receptor (FXR) agonist, in approximately 60 non-alcoholic steatohepatitis (NASH) patients after 16 weeks of treatment.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates on Thursday, November 11, 2021,

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the third quarter 2021 after market close on Tuesday, November 9, 2021.